Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Chicago Capital LLC

Chicago Capital LLC lessened its stake in Edwards Lifesciences Co. (NYSE:EW) by 82.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,408 shares of the medical research company’s stock after selling 83,763 shares during the quarter. Chicago Capital LLC’s holdings in Edwards Lifesciences were worth $1,363,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Magnolia Capital Advisors LLC raised its holdings in shares of Edwards Lifesciences by 8.3% during the 4th quarter. Magnolia Capital Advisors LLC now owns 7,198 shares of the medical research company’s stock worth $533,000 after acquiring an additional 553 shares during the period. Comprehensive Financial Consultants Institutional Inc. grew its position in Edwards Lifesciences by 8.7% in the 4th quarter. Comprehensive Financial Consultants Institutional Inc. now owns 24,628 shares of the medical research company’s stock valued at $1,823,000 after acquiring an additional 1,971 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in Edwards Lifesciences by 3.7% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 18,816 shares of the medical research company’s stock valued at $1,393,000 after buying an additional 676 shares during the period. Capital Insight Partners LLC raised its position in Edwards Lifesciences by 3.6% in the 4th quarter. Capital Insight Partners LLC now owns 62,492 shares of the medical research company’s stock valued at $4,626,000 after purchasing an additional 2,164 shares in the last quarter. Finally, Independence Bank of Kentucky grew its stake in shares of Edwards Lifesciences by 60.4% during the fourth quarter. Independence Bank of Kentucky now owns 2,550 shares of the medical research company’s stock worth $189,000 after purchasing an additional 960 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity

In related news, VP Daniel J. Lippis sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at $1,717,841.12. This trade represents a 9.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,000 shares of company stock valued at $547,430. 1.27% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Down 1.4 %

NYSE:EW opened at $71.46 on Tuesday. The business’s 50 day moving average is $72.49 and its two-hundred day moving average is $69.73. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a market cap of $42.15 billion, a PE ratio of 10.31, a P/E/G ratio of 3.72 and a beta of 1.11.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on EW. The Goldman Sachs Group upped their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their price target for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Barclays upped their price objective on Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, December 2nd. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Finally, Piper Sandler lowered their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating for the company in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and an average price target of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.